四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.
四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)
(Stock Code: 0460)

POSITIVE PROFIT ALERT

This announcement is issued by Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

The board of directors of the Company (the "**Board**") would like to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Company for the six months ended 30 June 2025 (the "**Period**") and the information currently available to the Board, the Group is expected to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the Period.

The factors affecting the financial results of the Group for the Period primarily include the following:

(1) the high growth in the medical aesthetics business, representing a growth rate between 50% to 60% as compared to the same period last year;

(2) the innovative drug business having entered a harvest period, characterized by a gradual reduction of research and development expenses on innovative drugs, continuous emergence of newly approved products, smooth commercialization of new products, as well as the continuous growth in the segment revenue of that sector;

(3) the decline of the generic drug business being progressively narrowed year-on-year; and

(4) the Company maintaining a solid financial position with sufficient cash reserves.

From January 2024 to the end of July 2025, the Group has received NDA approvals for a total of 41 new medical aesthetics and pharmaceutical products, including a total of 9 medical aesthetic products comprising the Company's independently developed major Class 3 medical device products, the PCL filler (brand name: Qingyan®), PLLA filler (brand name: Huiyanzhen® and Sifuyan®) and the exclusively distributed Class 3 major medical device product, the dual-wave radio frequency microneedle system Sylfirm X, and a total of 32 new pharmaceutical products (including supplementary applications), comprising the Company's independently developed Class 1 innovative drug Bireociclib tablets (brand name: Xuanyuening®), Ganagliflozin Proline tablets (brand name: Huiyoujing®), the first domestically produced generic drug, the Insulin Degludec and Insulin Aspart Injection (brand name: Huiyoujia®) and the Insulin Degludec Injection (brand name: Huiyouda®). The Group expects that the simultaneous launch of such a significant amount of major new products will inject strong momentum for the Group's future revenue and profit growth. The Group is confident in its development prospects in the future.

The Board would like to remind the Shareholders and potential investors that the information contained in this announcement has not been reviewed or audited by the independent auditor or the audit committee of the Company and may be subject to adjustments. The actual results of the Company for the Period may differ from the information contained in this announcement. Detailed financial information of the Company for the Period will be disclosed in the interim results announcement of the Company, which is expected to be published before the end of August 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 1 August 2025

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.